The Buffett Lens

Well, howdy there, neighbor. Imagine you're out on a sunny afternoon, strolling through a vast field of rich, black soil that's been plowed and planted just right. That's a bit like Range Resources Corporation—a company that's been digging deep into the Appalachian region, pulling out natural gas, natural gas liquids, and a touch of oil, all while tending to its fields with care. It's not about flashy fireworks or quick thrills; it's the steady work of a farmer who knows the land and harvests what it yields. I've always liked businesses that remind me of that—ones built on solid ground, not hot air.

Now, let's talk about what makes Range tick, and how it lines up with the things I've always preached. First off, this outfit has shown a knack for earning power that's consistent, like a reliable old tractor that keeps chugging along. Look at their revenue over the last eight quarters—it's climbed from zero to over a billion dollars, and net income followed suit, hitting about $300 million in some quarters. Over the last four quarters alone, they've raked in $3.2 billion in revenue and $900 million in net income. That's the kind of steady growth that warms my heart, far better than chasing quarterly fireworks that might fizzle out.

Their return on equity is another feather in the cap—19.6% lately, and averaging 9.2% over five years. As I used to say back in '79, it's the earnings rate on equity capital that matters most, not just per-share games. And they're doing it without piling on debt; their debt-to-equity ratio is just 0.21 times, which means they're rowing with a light boat, not one loaded down with rocks. That's smart—keeps the ship afloat even when the waters get choppy. Plus, they've got a wide moat, scoring 74 out of 100, thanks to their asset base and cost advantages. It's like owning the best fishing spot on the lake; others might try to cast their lines nearby, but you've got the prime real estate, keeping competitors at bay and profits flowing.

Management-wise, it's not a bad crew. Insider ownership is modest at 1.2%, but institutional investors hold over 100% of the shares—that's a lot of watchful eyes. It's not the ideal setup I'd dream of, where managers are rowing their own boat with big stakes in it, but it's solid. As I noted in '90, much of the value comes from the folks running the show, and here, they seem to be doing their stuff without too much fuss.

Of course, no farm is without its weeds, and I wouldn't be honest if I didn't mention the risks. The energy business can be fickle—like weather that turns from sunshine to storm overnight. Commodity prices for gas and oil swing around, and with inflation or global events, they could pinch profits. Range's operations are mostly in the Appalachian basin, which is good for focus but bad if regional issues pop up, like regulatory changes or environmental worries. And while their moat is decent, it's not unbreachable; new tech or cheaper competitors could sneak in. Their market cap of $9.7 billion at $41.17 a share might look attractive with a P/E of 11.4 times, P/B of 2.2 times, and EV/EBITDA at 6.9 times, but remember, as I said in '96, what counts is intrinsic value, not just book numbers. We can't match past growth forever, and market moods can play tricks on earnings.

That said, if you're patient—like waiting for crops to ripen—this could be a sensible buy. Range is in a sector I understand: energy, with a focus on natural gas that's cleaner and more in demand than ever. Their cost advantages mean they can weather price dips better than most, and with low debt, they're positioned for steady returns over time. The Buffett Score of 73 out of 100 suggests it's got legs, aligning with my love for high ROE, economic moats, and businesses that earn without undue risk. If you're thinking long-term, say five or ten years, and not betting the farm on short-term swings, this might just be the kind of investment that rewards patience. For those looking to act on this, the ticker for Range Resources Corporation on eToro is $RRC. Stay curious, my friend—investing's a marathon, not a sprint.

My friends, imagine you're walking through a bustling pharmacy, and there's this one shelf stocked with medicines that tackle some of the trickiest ailments the human body can throw at us—things like uncontrollable movements from certain diseases or hormonal imbalances that mess with people's lives. That's a bit like what Neurocrine Biosciences is all about. They're not peddling everyday aspirin; they're in the business of discovering and selling specialized drugs for neurological, psychiatric, and other disorders. It's a niche, but one where they've built a real foothold with products like INGREZZA for tardive dyskinesia or CRENESSITY for congenital adrenal hyperplasia. Think of it as a family-run apothecary that's grown into a respected shop, helping folks who need targeted relief.

Now, as I always say, the key to any investment is finding businesses that can earn a good return on the money they put to work, without piling on debt or funny accounting. Neurocrine fits that bill nicely. Their return on equity— that's just a way of measuring how efficiently they're using shareholders' money—stands at 14.7%, which is solid, especially when you look at their average over the last five years at 9%. And they do it with hardly any debt; their debt-to-equity ratio is a lean 0.13 times, meaning they're not borrowing big to grow. It's like rowing a boat with a steady current behind you, rather than fighting upstream with heavy oars.

What really catches my eye is their economic moat, that protective ditch around their castle that keeps competitors at bay. Here, it's built on strong patent protection and a knack for research and development. They've got a score of 68.7 out of 100 on that front, which isn't perfect but shows they've got barriers to entry. In a field like pharmaceuticals, where new discoveries can change the game, that's important. And they've grown their revenues impressively—from nothing much to $800 million in the last eight quarters, with last twelve months' revenues hitting $2.9 billion and net income at $500 million. It's like planting seeds and watching a garden flourish, year after year.

Of course, no business is without its warts, and I'd be remiss not to mention them humbly. The pharmaceutical world is competitive, with big players always lurking and regulations that can trip you up. Their management team has only 1.1% insider ownership, which might suggest the folks running the show don't have quite as much skin in the game as I'd prefer—though the high institutional ownership at over 100% (a bit of a quirk, but it means plenty of smart investors are watching closely). Valuation-wise, they're not exactly a bargain at a price-to-earnings ratio of 28.6 times and a price-to-book of 4.2 times. That's not outrageously high, but in my book, I'd rather pay less for more certainty. And while their growth has been strong, pharma is full of R&D risks—drugs that look promising might not pan out, or competitors could come up with something better.

Still, looking at the long term, Neurocrine has the potential to keep compounding value if they stick to their knitting. They've shown they can innovate and build a portfolio of products that people need, and with a Buffett Score of 68.5 out of 100, it's not a slam dunk but certainly worth considering. At today's price of around $147 a share and a market cap of $14.8 billion, it strikes me as a sensible buy for patient investors who believe in the power of steady earnings over time. We're talking about intrinsic value here, not just what's on the books—growth that can't be sustained forever, but a foundation that could support it for years to come if management keeps rowing effectively. Patience is key; markets will fluctuate, but businesses like this can reward those who hold on.

For those looking to act on this, the ticker for Neurocrine Biosciences, Inc. on eToro is $NBIX.